Kalmeijer M D, Coertjens H, van Nieuwland-Bollen P M, Bogaers-Hofman D, de Baere G A J, Stuurman A, van Belkum A, Kluytmans J A J W
Department of Pharmacy, Academic Medical Center, University of Amsterdam, 1100 DD Amsterdam, The Netherlands.
Clin Infect Dis. 2002 Aug 15;35(4):353-8. doi: 10.1086/341025. Epub 2002 Jul 15.
The objective of this study was to determine whether use of mupirocin nasal ointment for perioperative eradication of Staphylococcus aureus nasal carriage is effective in preventing the development of surgical site infections (SSIs). A randomized, double-blind, placebo-controlled design was used. Either mupirocin or placebo nasal ointment was applied twice daily to 614 assessable patients from the day of admission to the hospital until the day of surgery. A total of 315 and 299 patients were randomized to receive mupirocin and placebo, respectively. Eradication of nasal carriage was significantly more effective in the mupirocin group (eradication rate, 83.5% versus 27.8%). In the mupirocin group, the rate of endogenous S. aureus infections was 5 times lower than in the placebo group (0.3% and 1.7%, respectively; relative risk, 0.19; 95% confidence interval, 0.02-1.62). Mupirocin nasal ointment did not reduce the SSI rate (by S. aureus) or the duration of hospital stay.
本研究的目的是确定围手术期使用莫匹罗星鼻软膏根除金黄色葡萄球菌鼻腔定植是否能有效预防手术部位感染(SSI)。采用随机、双盲、安慰剂对照设计。从入院当天至手术当天,每天两次对614例可评估患者使用莫匹罗星或安慰剂鼻软膏。分别有315例和299例患者被随机分配接受莫匹罗星和安慰剂治疗。莫匹罗星组鼻腔定植的根除效果显著更好(根除率分别为83.5%和27.8%)。在莫匹罗星组,内源性金黄色葡萄球菌感染率比安慰剂组低5倍(分别为0.3%和1.7%;相对风险为0.19;95%置信区间为0.02 - 1.62)。莫匹罗星鼻软膏并未降低(由金黄色葡萄球菌引起的)SSI发生率或住院时间。